Pediatric Oncology
Source-checked note: this page is educational and was last checked against public pediatric oncology sources on 2026-05-22. It does not replace pediatric oncology care.
TL;DR
Childhood cancer is rare but high-impact. Its biology, treatment principles, and ethical framework differ meaningfully from adult oncology, and survivorship is now a defining concern. Use dated population sources for incidence and survival: NCI/SEER or ACS for the United States, and INCA for Brazil. Do not turn population survival into an individual prognosis. Sources: [1], [3], [11]
Statistics Source Gate
| Region | Current source to use | Safe wording |
|---|---|---|
| United States | NCI childhood cancer fact sheet / SEER / ACS current annual estimates | Separate ages 0-14, 0-19, and AYA definitions; survival varies strongly by diagnosis |
| Brazil | INCA Estimativa 2026-2028 pediatric pages | INCA estimates 7,560 new cancer cases per year in ages 0-19 for 2026-2028 |
| Survivorship | CCSS and review literature | Late effects are common; risk depends on diagnosis, treatment exposure, age, and follow-up |
1. Why pediatric oncology is its own field
Pediatric tumors differ from adult cancers in several key ways:
- Different histologies dominate. Acute lymphoblastic leukemia (ALL), CNS tumors, lymphomas, neuroblastoma, Wilms tumor, soft-tissue and bone sarcomas, retinoblastoma — embryonal and developmental in origin, not the carcinomas that dominate adult oncology.
- Lower mutation burden. Pediatric tumors typically have far fewer somatic mutations than adult tumors; drivers are often single fusions or recurrent events (e.g., MYCN amplification in neuroblastoma, EWSR1-FLI1 in Ewing sarcoma, BRAF fusions in pediatric low-grade glioma).
- Higher chemo-sensitivity. Many pediatric cancers respond strongly to multi-agent chemotherapy that is too toxic for older adults.
- Developmental physiology. Drug metabolism, growth, organ maturation, and behavior all change therapy choices and toxicity windows.
- Cooperative-group framework. Most patients are treated on or after a Children's Oncology Group (COG) / SIOP / GBOP protocol — a very different evidence base than adult community oncology.
2. Common pediatric cancers
| Cancer | Notes |
|---|---|
| Acute lymphoblastic leukemia (ALL) | Most common; contemporary pediatric B-ALL outcomes are favorable in risk-adapted protocols, but prognosis depends on risk group, response, access, and relapse status; CD19 CAR-T is used in defined relapsed/refractory cases |
| CNS tumors | Now the leading cause of cancer death in childhood; gliomas (low- and high-grade), medulloblastoma, ependymoma |
| Lymphomas | Hodgkin and non-Hodgkin; many pediatric protocols have favorable outcomes, but risk group and late effects matter |
| Neuroblastoma | Sympathetic nervous system; risk-stratified by MYCN status, age, stage |
| Wilms tumor (nephroblastoma) | Excellent prognosis with surgery + chemo ± radiation |
| Sarcomas | Soft-tissue (rhabdomyosarcoma) and bone (osteosarcoma, Ewing) |
| Retinoblastoma | Eye tumor; germline RB1 mutation in heritable form |
| Hepatoblastoma | Liver; surgical resection central |
| Germ cell tumors | Variable; chemosensitive |
Pediatric low-grade glioma (pLGG) is the most common CNS tumor in children — increasingly conceptualized as a chronic disease with focus on functional outcomes and targeted therapy (BRAF/MEK inhibitors for MAPK-pathway alterations). Sources: [2]
3. Treatment principles
- Risk-adapted therapy. Stratification by stage, biology, and response — escalating intensity for high-risk, de-escalating for low-risk to reduce late effects.
- Multimodal protocols. Surgery + chemotherapy + radiation + (increasingly) targeted/immunotherapy.
- Clinical trial enrollment. Cooperative-group trials are a major reason outcomes have improved in many pediatric cancers.
- Multidisciplinary team. Pediatric oncologist, surgeon, radiation oncologist, pathologist, pharmacist, nurse, social worker, child-life specialist, school liaison, psychologist, palliative care.
- Family-centered care. The "patient" is the family — communication, decision-making, and support involve parents, siblings, and the child appropriate to age.
4. Late effects and survivorship — the new mainstream
As long-term survival has improved for many pediatric cancers, the focus has shifted to what happens decades later. The Childhood Cancer Survivor Study (CCSS) and similar cohorts have shown: Sources: [1]
- ~95 % of survivors have a significant chronic condition by age 45.
- The most common severe / life-threatening late effects:
- Endocrine (~44 %) — hypothyroidism, growth hormone deficiency, infertility.
- Subsequent neoplasms (~7 %) — radiation-induced thyroid, breast, sarcomas.
- Cardiovascular (~5 %) — anthracycline-induced cardiomyopathy, radiation-related coronary disease.
- Highest-risk groups: brain tumor survivors who received cranial radiation (~70 % serious health problems) and allogeneic HSCT recipients (~60 %).
- Lowest-risk: solid tumors treated with surgery alone or minimal chemo (similar to general population).
Long-term follow-up is now standard of care in major pediatric oncology centers. Brazilian centers have developed survivorship clinics, but coverage and access remain uneven across the country.
5. Ethical and regulatory specifics
Pediatric research has stricter rules than adult research:
- Assent + parental consent. The child gives age-appropriate assent; the parent or legal guardian gives consent. Both are required when the child is capable of assenting.
- Risk thresholds. US Common Rule §50.50–55 categorizes pediatric research by risk level and requires IRB justification for each.
- Therapeutic vs. non-therapeutic. Greater scrutiny for non-therapeutic procedures.
- Vulnerable population. Pediatric patients are categorically vulnerable; protocols must justify minimization of risk and procedures.
- Pediatric-specific endpoints and toxicity grading (CTCAE-Ped).
- Long follow-up obligations for late effects.
In Brazil, CONEP/Plataforma Brasil review pediatric protocols with extra scrutiny; the Lei 14.874/2024 reinforces pediatric protections. See Regulatory & ethics.
6. Brazilian context
- INCA estimates 7,560 new pediatric/adolescent cancer cases per year in Brazil for each year of the 2026-2028 triennium; survival and cure language should be reported by diagnosis, stage, access, and region, not as a single blanket percentage.
- GRAACC (São Paulo) is the largest dedicated pediatric oncology center; GBOP (Brazilian Pediatric Oncology Group) coordinates multicenter cooperative trials.
- Hospital de Câncer de Barretos, Hospital A.C. Camargo, Hospital Pequeno Príncipe (Curitiba), Boldrini (Campinas), Hospital Israelita Albert Einstein, and several public-academic services host major pediatric programs.
- Lei dos 60 dias (12.732/2012) and SUS oncology pathways apply.
- Childhood cancer awareness campaigns and school-leave protections have expanded since the 2000s.
- A persistent challenge: late presentation — diagnostic delay is a major driver of poorer outcomes in some regions.
7. Where technologists can contribute
- Survivorship registries and risk calculators — automate late-effect surveillance reminders by treatment exposure.
- Trial-matching tools — pediatric trials are scarce; matching is high-stakes.
- Family communication tools — multilingual, age-appropriate explainers and decision aids.
- Imaging analysis with pediatric-specific datasets — adult-trained models often fail on pediatric anatomy.
- Wearables and ePROs for symptom tracking in long-running treatment.
- Diagnostic delay — community-level alerting and referral pathways for nonspecific pediatric symptoms.
For broader background: Clinical trials, Regulatory & ethics, Psycho-oncology.
See also
References
- Bhatia S, Tonorezos ES, Landier W. Clinical Care for People Who Survive Childhood Cancer: A Review. JAMA 2023;330:1175-1186. PMID 37750876. https://doi.org/10.1001/jama.2023.16875
- Fangusaro J, Jones DT, Packer RJ, et al. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro Oncol 2024;26:25-37. PMID 37944912. https://doi.org/10.1093/neuonc/noad195
- U.S. National Cancer Institute. Childhood cancers. https://www.cancer.gov/types/childhood-cancers
- American Cancer Society. Cancers in Children. https://www.cancer.org/cancer.html
- Cleveland Clinic. Childhood cancers (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
- Instituto Nacional de Câncer (INCA). Estimativa: incidência de câncer no Brasil — câncer infantojuvenil. https://www.inca.gov.br/
- GRAACC — Grupo de Apoio ao Adolescente e à Criança com Câncer. https://www.graacc.org.br/
- A.C. Camargo Cancer Center. https://accamargo.org.br
- Fundação do Câncer (Brasil). https://www.cancer.org.br/
- Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
- Instituto Nacional de Câncer (INCA). Câncer infantojuvenil - estimativa 2026. https://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa/estado-capital/brasil/cancer-infantojuvenil